The Gut Barrier Protocol — Colostrum and Zinc First, BPC-157 + KPV as the Experiment
A gut barrier protocol that puts the compounds with human trials first and the peptides last. Layer 0 is the search for a cause a supplement cannot fix: celiac disease, inflammatory bowel disease, NSAIDs, alcohol. Layer 1 is bovine colostrum and zinc (as zinc carnosine), the two agents shown in randomized human studies to blunt the rise in intestinal permeability caused by NSAIDs and heavy exercise. Layer 2 is microencapsulated sodium butyrate, with a 12-week IBS trial behind one symptom. Layer 3 is BPC-157 and KPV, optional and labelled honestly: rodent data, no human trial, community doses. Graded D to the peptide layer that gives the protocol its name.
Daily Schedule
Timing and dosage for each step
Layer 0 — before any supplement: celiac serology, CRP and fecal calprotectin, a medication and alcohol review, and a two-week symptom diary
10 g
A measurement step, not a dose. Blood in the stool, weight loss, night-time symptoms, fever or a raised calprotectin mean inflammatory bowel disease or something else that a gastroenterologist needs to see before you buy anything. The 10 g shown is the Layer 1 colostrum dose that follows.
Layer 1 — morning, away from other food, from week 0
10 g
10–20 g of bovine colostrum powder (standardized IgG ≥25%). The human data are on permeability: in a randomized crossover in 7 volunteers, colostrum prevented the threefold rise in lactulose:rhamnose ratio caused by 5 days of indomethacin, and the same was seen in 15 patients on long-term NSAIDs; in 14 days of heavy exercise in the heat, colostrum truncated the permeability rise by 70%. A separate trial of 1.7 g/kg for 7 days found no effect on permeability or performance in the heat. Evidence for a lab marker, not for symptoms.
Layer 1 — with meals, from week 0
30 mg
15–30 mg elemental zinc with food (zinc carnosine 75 mg/day delivers about 16 mg zinc and is the form in the permeability trials). In volunteers, indomethacin raised the lactulose:rhamnose ratio from 0.35 to 0.88; with zinc carnosine there was no significant rise. In the exercise study zinc carnosine alone truncated the permeability rise by 70% and the combination with colostrum added benefit. Above 30 mg/day for months, add 1–2 mg copper.
Layer 2 — with meals, from week 4, if IBS-type symptoms persist
300 mg
300 mg/day of microencapsulated sodium butyrate, the dose and form in the 12-week randomized trial in irritable bowel syndrome: pain during defecation fell at 4 weeks and urgency and bowel habit improved at 12, while abdominal pain, flatulence and disordered defecation did not change significantly. Dietary fibre remains the larger butyrate source. Uncoated butyrate does not reach the colon.
Layer 3 — OPTIONAL experimental layer, oral capsule with breakfast and dinner, weeks 8–12 only
500 mcg
⚠️ No published human trial. BPC-157 has decades of rat gut-lesion data and a set of inflammatory bowel disease trials announced by its manufacturer whose results were never published. The 500 µg twice daily is this site's community convention, not a trial dose. Research peptide, not approved by the FDA or EMA. Skip this layer and the protocol stands.
Layer 3 — OPTIONAL experimental layer, oral capsule with breakfast and dinner, weeks 8–12 only
2 mg
⚠️ No published human trial. The evidence is two mouse colitis models, in which KPV sped recovery, restored body weight and reduced inflammatory infiltrate and myeloperoxidase, partly independent of the MC1 receptor. The 2 mg twice daily is a community convention. Research peptide. If you run peptides, run one at a time so an effect or a side effect can be attributed.
Read This Before the Protocol
"Leaky gut" is a lab finding, not a diagnosis, and a supplement protocol cannot replace the search for what is causing your symptoms. Blood in the stool, unintended weight loss, symptoms that wake you at night, fever, anemia or a family history of inflammatory bowel disease or celiac disease belong with a gastroenterologist before you buy a single capsule. Celiac serology, CRP and a fecal calprotectin are cheap and decide the direction. Daily NSAIDs and heavy alcohol are the two most common barrier insults in otherwise healthy people, and removing them does more than anything below.
The second thing to know is what the human trials measured. Every randomized human study on this page measured intestinal permeability, the lactulose:rhamnose ratio in urine after a sugar drink, in volunteers given an NSAID or made to exercise in the heat. Colostrum and zinc carnosine blunted that rise. None of those trials measured bloating, stool form or pain, and one well-designed colostrum trial found nothing at all. The butyrate trial measured symptoms in irritable bowel syndrome and moved one of them. That is the honest ceiling of this page.
The third: the peptides the old version of this protocol led with have never been tested in a human trial. BPC-157 has a large rat literature on gastrointestinal lesions and a set of inflammatory bowel disease trials announced by its Croatian manufacturer two decades ago whose results were never published. KPV has two mouse colitis models. Both are research peptides, both are kept here as an optional, labelled experiment, and the protocol is graded to them. The site's longer discussions are The Gut Barrier Protocol: Synergizing BPC-157 and KPV and KPV Peptide Deep Dive.
Layer 0 — Find the Cause
| Check | Why |
|---|---|
| Celiac serology (tTG-IgA with total IgA) | A treatable cause of permeability and malabsorption, missed for years |
| Fecal calprotectin, CRP | Raised means inflammation that needs imaging or endoscopy, not colostrum |
| Blood count, ferritin, B12 | Anemia or deficiency points to bleeding or malabsorption |
| Medication review | NSAIDs, PPIs, metformin, antibiotics in the last 6 months |
| Alcohol, diet, sleep, stress | Daily drinking and chronic sleep loss both raise permeability |
| Two-week symptom diary | Bristol stool scale, bloating 1–5, pain 1–5, meals and timing; your baseline for everything below |
Red flags that end this protocol before it starts: blood in the stool, weight loss, night-time symptoms, fever, a raised calprotectin, or new symptoms after 50. See a clinician.
Who This Is For, and Who Should Not Run It
For: adults with functional gut symptoms (bloating, irregular stools, food reactivity) whose Layer 0 workup is clean; people recovering from a course of antibiotics or a period of heavy NSAID use; endurance athletes who get gut symptoms during long or hot sessions, the group closest to the trial populations.
Not for, without a gastroenterologist:
- Diagnosed or suspected inflammatory bowel disease: the colostrum and butyrate layers may be reasonable adjuncts, but the plan is the specialist's, and the peptide layer has no place in it.
- Celiac disease: the treatment is a gluten-free diet, not a stack.
- Dairy allergy: colostrum is a dairy product.
- Immunosuppression, pregnancy, breastfeeding: no data for any layer; none for the peptides.
- Children: no data.
The Layer Logic
| Layer | What | Evidence grade | Who |
|---|---|---|---|
| 0 — Find the cause | Serology, calprotectin, medications, diary | — | Everyone |
| 1 — Colostrum 10–20 g + zinc | Blunt the permeability rise from NSAIDs and heat exercise | B for the lab marker, C for symptoms | Clean workup, from week 0 |
| 2 — Microencapsulated butyrate 300 mg | IBS symptoms | C | Persistent IBS-type symptoms at week 4 |
| 3 — BPC-157 + KPV | Rodent gut-lesion and colitis data | D, optional | Nobody needs it; weeks 8–12 only, one peptide at a time |
The protocol is graded D, to the layer that gives it its name and that some users will run. Layers 1 and 2 on their own are grade B to C.
Layer 1 — Colostrum and Zinc, Weeks 0–8
Bovine colostrum, 10–20 g of powder standardized to at least 25% IgG, in the morning away from other food. The human evidence is about permeability. In a randomized crossover in seven volunteers, five days of indomethacin tripled the lactulose:rhamnose ratio (0.36 to 1.17) on a whey control, and the rise did not occur when colostrum (125 ml three times daily) was taken alongside; fifteen patients on long-term NSAIDs showed the same pattern. In healthy men exercising in the heat for 14 days, colostrum truncated the exercise-induced permeability rise by about 70%. Against that, a placebo-controlled trial of 1.7 g/kg/day for seven days in trained and untrained men found no effect on permeability or on performance in the heat. Read the layer as "probably protective when something is actively insulting the barrier," not as a cure for symptoms. Profiles and background: Bovine Colostrum, Bovine Colostrum: IGF-1, Gut Repair, Immune Function.
Zinc, 15–30 mg elemental with meals, ideally as zinc carnosine (75 mg/day, about 16 mg zinc). Zinc carnosine is the form in the trials: in volunteers, indomethacin raised the lactulose:rhamnose ratio from 0.35 to 0.88, and no significant rise occurred when zinc carnosine was co-administered; in the heat-exercise study, zinc carnosine alone truncated the permeability rise by 70%, and combining it with colostrum gave an additional, earlier benefit. Zinc is also a cofactor for tight-junction proteins, which is the mechanistic reason it is here. Above 30 mg/day for more than a few weeks, add 1–2 mg of copper. Profile: Zinc.
Run Layer 1 for four weeks against your diary before adding anything.
Layer 2 — Butyrate, From Week 4 for IBS Symptoms
If stool urgency, pain with defecation or irregular bowel habit persist at week 4, add 300 mg/day of microencapsulated sodium butyrate with meals. That is the dose and form from a 12-week randomized trial in irritable bowel syndrome: pain during defecation fell by week 4, and urgency and bowel habit improved by week 12, while abdominal pain, flatulence and disordered defecation did not change significantly. Uncoated butyrate is absorbed before it reaches the colon, and dietary fibre remains the larger source of colonic butyrate. The form question is covered in Tributyrin vs Sodium Butyrate: Why the Form Matters. Profile: Sodium Butyrate.
Layer 3 — BPC-157 and KPV, Labelled Honestly
Nobody needs this layer. If you run it, you are running an experiment on yourself with compounds that have no published human trial, no established human dose, and no regulatory approval anywhere.
BPC-157, 500 µg orally twice daily with food, is the community convention; the 500 µg figure is not from a trial. The rat literature on gastric, esophageal and intestinal lesions is extensive and consistent, and inflammatory bowel disease trials were announced by the manufacturer in the 2000s without published results. Stable in gastric juice, which is why oral use for gut targets is plausible, and why the subcutaneous route adds nothing here. Background: BPC-157: Systemic Healing Peptide. Profile: BPC-157.
KPV, 2 mg orally twice daily, is likewise a convention. In two mouse colitis models, KPV sped recovery, restored body weight and reduced inflammatory infiltrates and myeloperoxidase, with effects at least partly independent of the MC1 receptor. That is the whole evidence base. Profile: KPV.
If you run the layer: weeks 8–12 only, after Layers 1 and 2 have had their chance; one peptide at a time for at least two weeks before adding the second, so an effect or a side effect can be attributed; buy only with a certificate of analysis; and stop at any new symptom. The protocol does not depend on this layer, and your diary will tell you whether it earned its place.
What Is Deliberately Left Out
- Zonulin testing. Commercial zonulin kits have unresolved specificity problems and no agreed reference range; a two-week symptom diary is a better instrument.
- Food-sensitivity IgG panels. Not validated for diagnosing anything; they measure exposure.
- Antimicrobial "SIBO protocols" and herbal cleanses. Diagnosis first; a breath test and a gastroenterologist, not a supplement page.
- L-glutamine and probiotics as layers. Both have their own profiles (L-Glutamine, Akkermansia) and their own, separate evidence; adding them here would make the diary uninterpretable.
Monitoring
| Marker | When | What you are looking for |
|---|---|---|
| Symptom diary: Bristol scale, bloating 1–5, pain 1–5 | Daily, from two weeks before Layer 1 | Weekly averages improving by a full point against baseline |
| Fecal calprotectin, CRP | Week 0; repeat if symptoms worsen | Normal and stable; a rise means a clinician, not another layer |
| Celiac serology, ferritin, B12 | Week 0 | Normal; if not, treat the cause |
| Body weight | Weekly | Stable; loss is a red flag |
| Copper (if zinc above 30 mg/day beyond 8 weeks) | Week 12 | Normal |
| Lactulose:rhamnose or lactulose:mannitol permeability test | Optional, week 0 and 12, where available | The only validated marker the trials used; interpret with the diary, not alone |
Exit Criteria
- Red flag at any point (blood, weight loss, night symptoms, fever, rising calprotectin): stop and see a clinician.
- Week 8, Layers 1 and 2 have changed nothing in the diary: the problem is not barrier permeability. Stop; take the diary and the Layer 0 results to a gastroenterologist.
- Week 12, the peptide layer has changed nothing against the week-8 baseline: drop it. That is the expected result, and running it longer does not change the evidence.
- Symptoms resolved: stop the peptides, keep the diet and alcohol changes, keep colostrum and zinc only through periods of NSAID use or heavy training, where the trials actually apply, and let the rest go.
Related Research
- The Gut Barrier Protocol: Synergizing BPC-157 and KPV for Complete GI Repair
- Colostrum + BPC-157: The Advanced Gut Repair Protocol for Leaky Gut and IBD
- Bovine Colostrum: IGF-1, Gut Repair, Immune Function, and Athletic Recovery
- KPV Peptide Deep Dive: Gut Inflammation and Leaky Gut
- Tributyrin vs Sodium Butyrate: Why The Form Matters